Association between polymorphisms in phospholipase A\(_2\) genes and the plasma triglyceride response to an n-3 PUFA supplementation: a clinical trial

Bénédicte L Tremblay\(^1\), Hubert Cormier\(^1\), Iwona Rudkowska\(^2\), Simone Lemieux\(^1\), Patrick Couture\(^1,2\) and Marie-Claude Vohl\(^1,2\)*

**Abstract**

**Background:** Fish oil-derived long-chain omega-3 (n-3) polyunsaturated fatty acids (PUFAs), including eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA), reduce plasma triglyceride (TG) levels. Genetic factors such as single-nucleotide polymorphisms (SNPs) found in genes involved in metabolic pathways of n-3 PUFA could be responsible for well-recognized heterogeneity in plasma TG response to n-3 PUFA supplementation. Previous studies have shown that genes in the glycerophospholipid metabolism such as phospholipase A\(_2\) (PLA\(_2\)) group II, IV, and VI, demonstrate changes in their expression levels in peripheral blood mononuclear cells (PBMCs) after n-3 PUFA supplementation.

**Methods:** A total of 208 subjects consumed 3 g/day of n-3 PUFA for 6 weeks. Plasma lipids were measured before and after the supplementation period. Five SNPs in PLA2G2A, six in PLA2G2C, eight in PLA2G2D, six in PLA2G2F, two in PLA2G4A, five in PLA2G6, and nine in PLA2G7 were genotyped. The MIXED Procedure for repeated measures adjusted for age, sex, BMI, and energy intake was used in order to test whether the genotype, supplementation or interaction (genotype by supplementation) were associated with plasma TG levels.

**Results:** The n-3 PUFA supplementation had an independent effect on plasma TG levels. Genotype effects on plasma TG levels were observed for rs2301475 in PLA2G2C, rs818571 in PLA2G2F, and rs1569480 in PLA2G4A. Genotype x supplementation interaction effects on plasma TG levels were observed for rs1805018 in PLA2G7 as well as for rs10752979, rs10737277, rs7540602, and rs3820185 in PLA2G4A.

**Conclusion:** These results suggest that SNPs in PLA\(_2\) genes may influence plasma TG levels during a supplementation with n-3 PUFA. This trial was registered at clinicaltrials.gov as NCT01343342.

**Keywords:** Gene-diet interactions, Plasma lipid levels, Omega-3 fatty acids, Phospholipase, Nutrigenetics

**Background**

Cardiovascular disease (CVD) is the leading cause of mortality worldwide [1]. Triglyceride (TG) is an independent risk factor of CVD [2]. Fish oil-derived long-chain omega-3 (n-3) polyunsaturated fatty acids (PUFAs), including eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA) play a significant role in preventing CVD [3]. The potential underlying mechanisms of n-3 PUFAs for reducing CVD risk are related to their hypo-triglyceridemic, anti-inflammatory, anti-atherogenic, and anti-arrhythmic effects [4]. Health organizations around the world currently recommend consumption of EPA and DHA to reduce CVD risk [5-8]. More specifically, The American Heart Association recommends an intake of 2 to 4 g of EPA/DHA per day for patients who need to lower their TG levels [5].

Yet, there is a well-recognized heterogeneity in the plasma TG response to n-3 PUFA supplementation [9].
For example, in the Fish Oil Intervention and Genotype (FINGEN) Study, 31% of all volunteers showed no reduction in plasma TG after taking 1.8 g EPA and DHA per day for 8 weeks [10]. The inter-individual variability observed in the plasma lipid response to an n-3 PUFA supplementation may partly result from genetic variations in genes involved in metabolic pathways of n-3 PUFA [9,11,12]. Understanding the genetic determinants of inter-individual variability to n-3 PUFA supplementation would provide a more rational basis for advising individuals on intake levels likely to achieve optimal reduction in CVD risk [9].

Our team worked on differences in metabolomic and transcriptomic profiles between responders and non-responders to an n-3 PUFA supplementation and found that the lipid metabolism pathways appear to be one of the most different between those two groups [13]. Genes in the glycerophospholipid metabolism such as phospholipase A₂ (PLA₂) group II, IV, and VI had changes in their expression levels after n-3 PUFA supplementation [13].

The PLA₂ represents an important superfamily of enzymes that catalyze the hydrolysis of the ester bond at the sn-2 position of phospholipids to yield non-esterified fatty acids such as AA and lysophospholipids [14]. Usually, these products lead to the generation of a variety of downstream signaling molecules including prostaglandins, leukotrienes, lysophospholipids, platelet activating factor (PAF), and oxidized lipids [15-20]. AA release by PLA₂ catalytic reaction is the initial and rate-limiting step for the biosynthesis of eicosanoids [21]. Currently these enzymes are classified into six major groups with many subgroups, depending on their functions and cellular locations: the secreted PLA₂ (sPLA₂), lipoprotein-associated PLA₂ (Lp-PLA₂), cytosolic PLA₂ calcium-dependent (cPLA₂), cytosolic PLA₂ calcium-independent (iPLA₂), lysosomal PLA₂ (iPLA₂) and adipose-specific PLA₂ (adPLA₂) [21]. In addition, elevated plasma PLA₂ activity, likely sPLA₂G2A, is an independent risk factor for CVD [22,23] and variations on the PLA₂G4A gene are associated with a CVD phenotype mediated by dietary PUFAs [24].

The objective of the present study is to examine whether genetic variations in PLA₂ genes influence plasma TG levels of healthy overweight adults following an n-3 PUFA supplementation.

**Methods**

**Study population**

A total of 254 subjects from the greater Quebec City metropolitan area were recruited to participate in the study between September 2009 and December 2011 via electronic messages sent to university students and employees as well as advertisements in local newspapers. The participants had to be between 18 and 50 years old, have a body mass index (BMI) between 25 and 40 kg/m², be non-smokers, and with no current lipid-lowering medications. They also needed to be free of any thyroid or metabolic disorders requiring treatment, e.g. diabetes, hypertension, severe dyslipidemia, and coronary heart disease (CHD). Subjects were not included if they had taken n-3 PUFA supplements for at least 6 months prior to the beginning of the study. A total of 210 subjects completed the intervention protocol and 208 had plasma TG levels data available for further analyses. The experimental protocol was approved by the Ethics Committees of Laval University Hospital Research Center and Laval University. The trial was registered at clinicaltrials.gov as NCT01343342.

**Study design and diets**

First, subjects followed a two-week run-in period during which they received dietary instructions by a trained registered dietitian to achieve the recommendations from Canada’s Food Guide to Healthy Eating. They were asked to apply these dietary recommendations and maintain their body weight stable throughout the protocol. The following instructions were given to ensure stable n-3 PUFA dietary intake: do not exceed two fish or seafood servings per week (maximum 150 g), prefer white flesh fish to fatty fish (examples were given), and avoid enriched n-3 PUFA food such as milk, juices, bread, and eggs. In addition, subjects were not allowed to take n-3 PUFA supplementation (such as flaxseed), vitamins, or natural health products during the protocol. They were also asked to limit their alcohol consumption to two drinks per week.

Second, after the two-week run-in period, subjects received a bottle containing needed n-3 PUFA capsules (Ocean Nutrition, Nova Scotia, Canada) for the following six weeks of supplementation. Subjects had to take five capsules per day (1 g of fish oil concentrate each) providing a total of 3 g of n-3 PUFA (including 1.9 g EPA and 1.1 g DHA) per day. Compliance was assessed from the return of bottles and by measuring the incorporation of EPA and DHA in plasma phospholipids (PL). The participants were asked to report any deviation during the protocol, write down their alcohol and fish consumption as well as the side effects of supplementation. Before each phase, subjects received detailed written and oral instructions on their diet.

A registered dietitian showed the participants how to complete a 3-day (2 weekdays and 1 weekend day) food journal before and after n-3 PUFA supplementation. Nutrition Data System for Research software version 2011 (Nutrition Coordinating Center (NCC), University of Minnesota, Minneapolis, MN, USA) was used to analyse dietary intakes.

**Anthropometric measurements**

Body weight, height, and waist girth were measured according to the procedures recommended by the Airlie
SNPs, and two were located in exons and resulted in amino acid changes: rs6426616 (Gln→Arg), rs584367 (Ser→Gly), rs1805017 (Ser→Thr). While most of the SNPs selected were intronic, one PLA2G2C SNP, one PLA2G2D SNP, and two PLA2G7 SNPs were located in exons and resulted in amino acid changes: rs6426616 (Gln→Arg), rs584367 (Ser→Gly), rs1805017 (Arg→His), and rs1805018 (Ile→Thr).

Biochemical parameters
Blood samples were collected from an antecubital vein into vacutainer tubes containing EDTA after 12-hour overnight fast and 48-hour alcohol abstinence. Blood samples were drawn before the run-in period to identify and exclude participants with metabolic disorders. Afterwards, the selected participants had blood samples taken before and after the n-3 PUFA supplementation period. Plasma was separated by centrifugation (2,500 g for 10 min at 4°C), and samples were aliquoted and frozen for subsequent analyses. Plasma total cholesterol (TC) and TG concentrations were measured using enzymatic assays [26]. The high-density lipoprotein cholesterol (HDL-C) fraction was obtained after precipitation of very-low-density lipoprotein (VLDL) and low-density lipoprotein (LDL) particles in the infranatant with heparin manganese chloride [27]. LDL cholesterol (LDL-C) was calculated with the Friedewald formula [28]. Apolipoprotein B-100 concentrations were measured in plasma by the rocket immunoelectrophoretic method of Laurell, as previously described [29]. Plasma C-reactive protein (CRP) was measured by nephelometry (Prospec equipment Behring) using a sensitive assay [30].

Fatty acid composition of plasma phospholipids
According to a modified Folch method, plasma lipids were extracted with chloroform:methanol (2:1, by volume) [31]. Total PL were separated by thin layer chromatography using a combination of acetic acid and isopropyl ether. Fatty acids of isolated PL were then methylated and capillary gas chromatography was then used to obtain fatty acids profiles. This technique has been previously validated [32].

SNP Selection and genotyping
SNPs in PLA2G2A, PLA2G2C, PLA2G2D, PLA2G2F, PLA2G4A, PLA2G6, and PLA2G7 were identified with the International HapMap Project SNP database, based on the National Center for Biotechnology Information (NCBI) B36 assembly Data Rel phase II + III, build 126 (Table 1). Tagger procedure in Haploview software V4.2 was used to determine tag SNPs (tSNPs) using a minor allele frequency (MAF) of 5% and pairwise tagging (R² ≥ 0.80). The LD procedure in Haploview V4.2 was then used to examine linkage disequilibrium (LD) between 5 SNPs in PLA2G2A, 6 in PLA2G2C, 8 in PLA2G2D, 6 in PLA2G2F, 22 in PLA2G4A, 5 in PLA2G6, and 9 in PLA2G7 covering all common variations (MAF > 5%) in these genes. Most of the SNPs were in LD (R² ≥ 0.80), and the mean R² was 0.943 for PLA2G2A, 0.974 for PLA2G2C, 1.0 for PLA2G2D, 0.976 for PLA2G2F, 0.975 for PLA2G4A, 0.968 for PLA2G6, and 0.973 for PLA2G7. The SIGMA GenElute Gel Extraction Kit (Sigma-Aldrich Co., St. Louis, MO, USA) has been used to extract genomics DNA. Selected SNPs (Table 1) were genotyped using validated primers and TaqMan probes (Thermo Fisher Scientific, Waltham, MA, USA) [33]. DNA was then mixed with TaqMan Universal PCR Master Mix (Thermo Fisher Scientific), with a gene-specific primer and probe mixture (predeveloped TaqMan SNP Genotyping Assays; Thermo Fisher Scientific.) in a final volume of 10 µL. Thereafter, genotypes were determined using a 7500 Real-Time PCR System and analyzed using ABI Prism SDS version 2.0.5 (Thermo Fisher Scientific.). Minor allele homozygotes with a genotype frequency <5% were grouped with heterozygotes for statistical analyses.

Statistical analyses
All statistical analyses were performed with SAS Statistical Software V9.3 (SAS Institute, Cary, N.C., USA), except for the ALLELE Procedure, which was done with SAS Genetics V9.3. The ALLELE Procedure was used to verify departure from the Hardy-Weinberg equilibrium (HWE) and calculate MAF. Values that were not normally distributed were log₁₀ or negative reciprocal transformed before analysis. ANOVA was used to test for significant differences in metabolic characteristics between men and women at baseline with age, sex, and BMI included in the model. A paired t-test was used to test for significant differences between various nutrient intakes before and after n-3 PUFA supplementation. A linear regression using the stepwise bidirectional elimination approach was applied to assess which SNPs could explain part of the plasma TG level variance. The 61 SNPs were in HWE. First, the MIXED procedure for repeated measures was used to test for the effects of the genotype, supplementation and genotype × supplementation interaction on plasma TG in a model adjusted for age, sex, BMI, and energy intake. Secondly, ANOVAs adjusted for age, sex, BMI, energy intake, and pre-supplementation plasma TG levels were used to test the differences in TG levels after supplementation between genotypic groups. Statistical significance was defined as p ≤ 0.05.

Results
Allele frequencies of selected SNPs are shown in Table 1. All SNPs were in HWE. Therefore, associations with 61 SNPs were tested in statistical analyses. The percent coverage was 90% for PLA2G2A, 85% for PLA2G2C, 90% for PLA2G2D, 80% for PLA2G2F, 85% for PLA2G4A, 98% for PLA2G6, and 93% for PLA2G7. While most of the SNPs selected were intronic, one PLA2G2C SNP, one PLA2G2D SNP, and two PLA2G7 SNPs were located in exons and resulted in amino acid changes: rs6426616 (Gln→Arg), rs584367 (Ser→Gly), rs1805017 (Arg→His), and rs1805018 (Ile→Thr).
| Gene     | dbSNP No. | Sequence        | Position       | Allele frequency |
|----------|-----------|-----------------|----------------|------------------|
| PLA2G2A  | rs876018  | ATAC(A/)TGAT    | 3-UTR          | A (n = 352) 0.8421 T (n = 66) 0.1579 |
|          | rs955587  | GCCT(A/G)GACT   | Intron         | G (n = 352) 0.8381 A (n = 68) 0.1619 |
|          | rs3753827 | GTAA(G/)TCCC    | Intron         | G (n = 233) 0.55574 T (n = 185) 0.4426 |
|          | rs11573156| GAGC(C/G)AGCT   | 5-UTR          | C (n = 326) 0.7762 G (n = 94) 0.2238 |
|          | rs11573142| ATGC(C/T)TACC   | NearGene-5     | T (n = 406) 0.9667 C (n = 14) 0.0333 |
| PLA2G2C  | rs6426616 | AGCC(A/G)GCC    | Missense Q [Gln] -> R [Arg] | G (n = 249) 0.5929 A (n = 171) 0.4071 |
|          | rs12139100| GGGG(C/T)GAAG   | Stop-gain      | C (n = 356) 0.8476 T (n = 64) 0.1524 |
|          | rs10916716| ACCC(A/G)GGCC   | Intron         | A (n = 358) 0.8524 G (n = 62) 0.1476 |
|          | rs2301475 | AAAG(C/T)ATTC   | NearGene-5     | A (n = 294) 0.9667 C (n = 14) 0.0333 |
|          | rs11573156| GAGC(C/G)AGCT   | 5-UTR          | C (n = 326) 0.7762 G (n = 94) 0.2238 |
|          | rs11573142| ATGC(C/T)TACC   | NearGene-5     | T (n = 406) 0.9667 C (n = 14) 0.0333 |
| PLA2G2D  | rs578459  | CATC(A/T)TCCA   | 3-UTR          | T (n = 234) 0.5571 T (n = 186) 0.4429 |
|          | rs16823482| ATT(T/T)CTCAC   | Intron         | T (n = 399) 0.9500 C (n = 21) 0.0500 |
|          | rs3736979 | ACTG(G/A)TGTC   | Intron         | G (n = 309) 0.73574 A (n = 111) 0.2643 |
|          | rs584367  | GTGC(A/G)GCAT   | Missense S [Ser] -> G [Gly] | G (n = 262) 0.6238 A (n = 158) 0.3762 |
|          | rs1204589 | GAA(GT/C)AAAG   | Intron         | T (n = 381) 0.9071 C (n = 39) 0.0929 |
|          | rs679667  | CCCC(G/A)CTGC   | Intron         | G (n = 381) 0.9071 A (n = 39) 0.0929 |
|          | rs17354769| AACT(A/G)GGCC   | Intron         | A (n = 399) 0.9545 G (n = 19) 0.0455 |
|          | rs10916711| CTAC(T/C)TATT   | Intron         | T (n = 266) 0.6425 C (n = 148) 0.3575 |
| PLA2G2F  | rs12065685| GGGG(C/T)TCTG   | Non-coding exon| T (n = 369) 0.8786 C (n = 51) 0.1214 |
|          | rs6657574 | TGAC(C/T)TTGC   | Non-coding exon| C (n = 345) 0.8214 A (n = 75) 0.1786 |
|          | rs11582551| ATCT(C/T)TCTG   | Intron         | T (n = 303) 0.7214 C (n = 117) 0.2786 |
|          | rs818571  | CGCC(C/T)TTGC   | 3-UTR          | C (n = 296) 0.7048 T (n = 124) 0.2952 |
|          | rs631134  | ATTC(A/G)GTGA   | NearGene-5     | G (n = 335) 0.7976 A (n = 85) 0.2024 |
|          | rs11583904| TGAG(A/G)TGGA   | Intron         | A (n = 71) 0.169 G (n = 349) 0.831 |
| PLA2G4A  | rs979924  | TACA(C/T)TGCA   | NearGene-5     | C (n = 33) 0.0786 T (n = 387) 0.9214 |
|          | rs2076075 | ATTC(G/A)TATAC  | Intron         | G (n = 381) 0.9071 A (n = 39) 0.0929 |
|          | rs3736741 | TTCC(A/G)GGCT   | Intron         | A (n = 320) 0.7619 G (n = 100) 0.2381 |
|          | rs10911949| CTAA(C/T)GGCA   | Intron         | C (n = 222) 0.5286 T (n = 198) 0.4714 |
|          | rs10752979| TCTA(C/G)TTGT   | Intron         | A (n = 68) 0.1619 G (n = 352) 0.8381 |
|          | rs1160719 | TTTC(A/G)TTAT   | Intron         | A (n = 79) 0.1881 G (n = 341) 0.8119 |
|          | rs10737277| ATCC(G/C)ACAC   | Intron         | C (n = 231) 0.55 G (n = 189) 0.45 |
|          | rs12720702| AATA(A/G)CAAG   | Intron         | A (n = 386) 0.919 G (n = 34) 0.081 |
|          | rs7522213 | ATTA(C/T)ATCC   | Intron         | C (n = 403) 0.9595 T (n = 17) 0.0405 |
|          | rs7540602 | CTCT(G/T)GACA   | Intron         | G (n = 379) 0.9024 T (n = 41) 0.0976 |
|          | rs10157410| TTTT(C/G)ACTA   | Intron         | C (n = 57) 0.1357 G (n = 363) 0.8643 |
|          | rs12720497| CCAG(C/T)GACC   | Intron         | C (n = 262) 0.6238 T (n = 158) 0.3762 |
|          | rs4651331 | CAAG(C/T)AGCA   | Intron         | G (n = 101) 0.2405 T (n = 319) 0.7595 |
|          | rs1569480 | TCAC(A/G)TAGG   | Intron         | A (n = 236) 0.5619 G (n = 184) 0.4381 |
|          | rs10911935| ACTC(G/T)TGAT   | Intron         | G (n = 337) 0.8024 T (n = 83) 0.1976 |
|          | rs12359444| AAAA(C/T)CTGA   | Intron         | C (n = 76) 0.181 T (n = 344) 0.819 |
|          | rs11576330| CACA(C/T)TCAC   | Intron         | C (n = 38) 0.0905 T (n = 382) 0.9095 |
|          | rs10489410| TTTG(C/T)TAGT   | Intron         | G (n = 16) 0.0381 T (n = 404) 0.9619 |
|          | rs10911946| TTAG(C/T)TGAC   | Intron         | C (n = 299) 0.7119 T (n = 121) 0.2881 |
Baseline characteristics of the study participants are presented in Table 2. As required by inclusion criteria, men and women were overweight (mean BMI > kg/m^2) and had mean plasma TG levels slightly above the cut-off value of 1.13 mmol/l recommended by the American Heart Association (AHA) for optimal plasma TG levels [34]. Significant gender differences were observed for weight, HDL-C, TG, and CRP levels. Daily energy and nutrient intakes measured by a 3-day food record are presented in Table 3. After n-3 supplementation, energy, carbohydrate, protein, and saturated fat intakes including n-3 supplements were significantly different from the pre-supplementation period (p = 0.006, p < 0.0001, p = 0.002, and p < 0.0001 respectively). PUFA intakes after the supplementation (including fish oil capsules and food) were significantly higher (p = 0.0002).

Subjects were asked to limit their fish intake to no more than two servings per week (one serving of fish = 75 g). Based on the compliance questionnaire, the mean intake of fish was of 0.89 serving per week during the n-3 PUFA supplementation period. Accordingly, subjects who had consumed the maximum quantity of fish permitted each week (150 g) would have had an extra 0.43 g of EPA and DHA per day. Following the supplementation, TG levels decreased in 71.2% and increased in 28.8% of the subjects (delta mean ± SD = −0.25 ± 0.15 and 0.20 ± 0.19 mmol/l, respectively), as previously reported [35].

We further tested the independent effect of the genotype, the supplementation or the interaction (genotype by supplementation) on plasma TG levels. First, the supplementation had an independent effect on plasma TG levels (p < 0.0001), as expected. Secondly, three SNPS, one of PLA2G2C (rs2301475), one of PLA2G2F (rs818571), and one of PLA2G4A (rs10752979, rs10737277, rs7540602, and rs3820185) (Table 4). All associations remained significant after further adjustments

Table 2 Baseline characteristics of the study sample (n = 208)

| Characteristics | All | Men | Women | p* |
|-----------------|-----|-----|-------|----|
| Study population, n | 208 | 96 | 112 |
| Age, years | 30.8 ± 8.7 | 31.2 ± 8.1 | 30.5 ± 9.1 | 0.55 |
| Weight, kg | 81.4 ± 13.9 | 87.2 ± 13.4 | 76.4 ± 12.3 | <0.0001* |
| BMI | 27.8 ± 3.7 | 27.5 ± 3.6 | 28.2 ± 3.8 | 0.13 |
| Waist circumference, cm | 93.3 ± 10.8 | 94.8 ± 11.0 | 92.0 ± 10.4 | 0.06 |
| TC, mmol/L | 4.82 ± 1.01 | 4.80 ± 1.00 | 4.83 ± 1.02 | 0.75 |
| HDL-C, mmol/L | 1.46 ± 0.39 | 1.29 ± 0.31 | 1.61 ± 0.39 | <0.0001* |
| LDL-C, mmol/L | 2.79 ± 0.87 | 2.91 ± 0.87 | 2.70 ± 0.86 | 0.08 |
| TG, mmol/L | 1.23 ± 0.64 | 1.32 ± 0.74 | 1.15 ± 0.53 | 0.04* |
| Apolipoprotein B, g/l | 0.86 ± 0.25 | 0.89 ± 0.25 | 0.84 ± 0.25 | 0.12 |
| CRP, mg/L | 3.13 ± 7.10 | 1.66 ± 2.45 | 4.39 ± 9.24 | 0.02* |

Values are means ± SD. *p < 0.05.
* p value from ANOVA for the differences between men and women at baseline;
*values are log10 transformed;
*values are negative reciprocal transformed;
*values adjusted for age;
*values adjusted for age and BMI.

Table 1 Selected polymorphisms in phospholipase A2 genes (Continued)

| Polymorphism | Allele Distribution | Intron | n (control) | p |
|--------------|---------------------|--------|-------------|---|
| rs3820185    | CATG(G/T)TGAG       | Intron | 283         | 0.3326 |
| rs12746200   | CCAC(A/G)ATCA       | Intron | 384         | 0.9143 |
| rs11587539   | TAG(A/T)TTTG        | Intron | 243         | 0.5786 |
| rs5750546    | TAAG(A/G)AAAA       | Intron | 259         | 0.6167 |
| rs132989     | GGGG(G/A)ACAG       | Intron | 392         | 0.9333 |
| rs133016     | AGTG(A/G)ACCC       | Intron | 215         | 0.5119 |
| rs2235346    | TGCC(C/A)GGGG       | Intron | 200         | 0.4762 |
| rs2284060    | AATC(A/G)ACGC       | Intron | 228         | 0.5429 |
| PLA2G7       | rs12195701          | A      | 379         | 0.9024 |
| rs12528807   | CCAC(A/C)GATC       | Intron | 379         | 0.0857 |
| rs1421368    | ATGA(C/T)CTTA       | Intron | 34          | 0.081 |
| rs1421378    | TGAT(T/C)CGGA       | NearGene-5 | 244 | 0.41 |
| rs17288905   | TCAA(T/C)AGCA       | Intron | 378         | 0.9214 |
| rs1805017    | GATC(G/A)ACTT       | Intron | 304         | 0.7238 |
| rs1805018    | GAAAT(T/C)AGGG      | Intron | 403         | 0.9595 |
| rs6929105    | TGAAT(A/G)GATG      | Intron | 98          | 0.2333 |
| rs7756935    | GGGG(G/T)TTAGA      | Intron | 85          | 0.2024 |

Allelic frequencies were obtained using the ALLELE Procedure (SAS Genetics v9.3).
Table 3 Nutrient intakes before and after n-3 PUFA supplementation (n = 208)

| Dietary Intakes      | Pre-supplementation | Post-supplementation (including n-3 PUFA supplements) | P-values |
|----------------------|---------------------|-------------------------------------------------------|----------|
| Energy (kcal)        | 2273 ± 590          | 2186 ± 566                                            | 0.006    |
| Carbohydrate (g/d)   | 286.7 ± 78.9        | 263.4 ± 77.7                                          | <0.0001  |
| Protein (g/d)        | 97.8 ± 30.2         | 92.6 ± 29.6                                           | 0.002    |
| Total fat (g/d)      | 84.5 ± 29.2         | 86.6 ± 29.8                                           | 0.44     |
| SFA (g/d)            | 29.0 ± 12.0         | 25.4 ± 10.4                                           | <0.0001  |
| MUFA (g/d)           | 30.8 ± 11.8         | 29.6 ± 12.4                                           | 0.11     |
| PUFA (g/d)           | 15.2 ± 6.6          | 17.1 ± 6.9                                            | 0.0002   |

Values are means ± SD. p < 0.05. *p-values provided by a paired t-test.
MUFA = monounsaturated fatty acids; PUFA = polyunsaturated fatty acids; SFA = saturated fatty acids.

Table 4 Significant effects of the genotype, the n-3 supplementation and the genotype x supplementation on TG levels (n = 208)

| Genes  | SNPs       | Genotype | Supplementation | Interaction |
|--------|------------|----------|-----------------|-------------|
| PLA2G2C| rs2301475  | 0.0209   | <.0001          | 0.8703      |
| PLA2G2F| rs818571   | 0.0188   | <.0001          | 0.3958      |
| PLA2G7 | rs1805018  | 0.2383   | <.0001          | 0.0286      |
| PLA2G4A| rs10752979f| 0.9152   | <.0001          | 0.0273      |
| PLA2G4A| rs10737277 | 0.6696   | <.0001          | 0.0241      |
| PLA2G4A| rs7540602f | 0.1663   | <.0001          | 0.0344      |
| PLA2G4A| rs1569480  | 0.0203   | <.0001          | 0.7758      |
| PLA2G4A| rs3820185  | 0.4778   | <.0001          | 0.0231      |

*p values are derived from log10-transformed data.
All results were adjusted for age, sex, BMI, and energy intake.
The MIXED procedure (SAS v9.3) was used to test the interaction effects.

Discussion
In this study, we tested whether the plasma TG levels response of healthy overweight adults to n-3 PUFA supplementation is modulated by genes encoding PLA2. Our team observed that PLA2G2A, PLA2G2C, PLA2G2D, PLA2G2F, PLA2G4A, and PLA2G6 are modulated by n-3 PUFA supplementation, since they were differentially expressed in peripheral blood mononuclear cells (PBMCs) after supplementation [13]. PLA2 family was shown to be influenced by n-3 PUFA supplementation so we included PLA2G7 since its gene product is a secreted enzyme whose activity is associated with CHD biomarkers [36,37].
In the present study, we tested the independent effects of the supplementation, genotypes of selected SNPs in PL\(A_2\) genes, and genotype x supplementation interaction on plasma TG levels. As expected, n-3 PUFA supplementation significantly lowered plasma TG levels, a finding that is concordant with results reported in literature [10,38]. Moreover, three SNPs of PL\(A_2\) genes influenced TG levels independently of the supplementation. In addition, genotypes x supplementation interaction effects were observed for five SNPs as previously mentioned. These SNPs and interaction effects considerably contributed to explain inter-individual variability in plasma TG levels after n-3 PUFA supplementation. Despite the fact that some nutrient intakes were significantly different pre- and post-supplementation, further analyses taking into account changes in carbohydrate, protein and saturated fat intakes revealed that results remained the same (data not shown). SNPs of PL\(A_2G2D\), PL\(A_2G7\), and PL\(A_2G4A\) explained 5.9% of the variance in post TG supplementation, in a linear regression model.

Our study showed that genetic factors, especially SNPs of PL\(A_2G2C\), PL\(A_2G2F\), PL\(A_2G4A\), and PL\(A_2G7\) influenced plasma TG levels response to n-3 supplementation and therefore potentially explained the variability observed which is consistent with findings from other investigators [9,10,38]. PL\(A_2G2C\) and PL\(A_2G2F\) that are part of the sPL\(A_2\) group have been less studied. PL\(A_2G2C\) appears to be a non-functional pseudogene, unlike its rodent counterpart [39]. PL\(A_2G2F\) has a twofold preference for AA over linoleic acid in vitro and that its expression generally increases in the aorta consecutively with advance of atherosclerosis [40,41].

PL\(A_2G7\) encodes human Lp-PL\(A_2\), also known as platelet-activating factor acetylhydrolase (PAF-AH), which has been much largely studied in the literature [21]. Lp-PL\(A_2\) may play an important role in the pathophysiology of inflammation because it participates in the oxidative modification of LDL [42]. High levels of Lp-PL\(A_2\) mass and activity were associated with the risk of CHD, stroke, and cardiovascular mortality [43]. It also may be an emerging biomarker for improved cardiovascular risk assessment in clinical practice and a potential therapeutic target for primary and secondary prevention of CVD [43]. The rs1805017 G and rs1051931 A alleles of PL\(A_2G7\) gene were found to be associated with coronary artery disease (CAD) [44] yet, up to now, studies are inconclusive on the association between PL\(A_2G7\) variants and cardiovascular risk [43,45-47]. SNP rs1805018 tended toward significantly decreased expression of the PL\(A_2G7\) gene [44] and decreased Lp-PL\(A_2\) activity [48].

One of our selected SNPs, rs1805018 (I198T), was part of the SNPs that had a genotype x supplementation interaction and was in strong-LD with SNPs found in the literature, namely rs201554087 (V279P), rs1051931 (A379V), and rs1805017 (R92H) [48]. Consequently, we may suppose that the genotype x supplementation effect we observed with rs1805018 is partly the reflection of these other functional SNPs. Further analyses performed with ESEfinder 3.0 showed that rs1805018 located in the coding region may impact mRNA splicing. However, analyses with SIFT and PolyPhen-2 did not confirm the potential functional effect of this SNP since the amino acid change was considered tolerated or benign.

Therefore, the majority of genotype x supplementation effects were observed with SNPs within PL\(A_2G4A\) gene (rs10752979, rs10737277, rs7540602, and rs3820185). PL\(A_2G4A\) encodes a cPL\(A_2\) that is now considered a central enzyme for mediating eicosanoid production and thus plays a major role in inflammatory diseases. Indeed, PL\(A_2G4A\) hydrolysis of phospholipid substrates has high substrate specificity for AA at the sn-2 position [21]. The release of AA has been linked to the action of cPL\(A_2\), but release of DHA is less clear, although the action of iPL\(A_2\) has been suggested in literature [49,50]. In addition, a functional variant (rs12746200) was associated with CVD phenotype mediated by dietary PUFA [24]. Interestingly, our team demonstrated that participants who did not lower their TG levels (non-responders) had lower PL\(A_2G4A\) expression after n-3 PUFA supplementation and that PL\(A_2G4A\) was expressed in opposite direction for primary and secondary prevention of CVD [43]. The rs1805017 G and rs1051931 A alleles of PL\(A_2G7\) gene were found to be associated with coronary artery disease (CAD) [44] yet, up to now, studies are inconclusive on the association between PL\(A_2G7\) variants and cardiovascular risk [43,45-47]. SNP rs1805018 tended toward significantly decreased expression of the PL\(A_2G7\) gene [44] and decreased Lp-PL\(A_2\) activity [48].
[51–53]. Indeed, n-3 and AA activate PPAR-α to decrease TG and VLDL secretion and increase fatty acid oxidation in the liver. N-3 and AA also activate PPAR-γ in the adipose tissues to improve insulin sensitivity, increasing TG clearance, suppressing lipolysis and hepatic TG production, thus helping to decrease TG levels [54–56].

Conclusions

Data from the present study suggest that SNPs within PLA2 genes may modulate plasma TG levels after n-3 PUFA supplementation in healthy overweight adults. These results need to be replicated in other independent studies, therefore we will be able to better understand the potential functional mechanism underlying these genetic associations. In conclusion, these results indicate that gene-diet interaction effects may modulate the response of plasma TG levels to n-3 PUFA intakes and thus contribute to the explanation of the inter-individual variability observed.

Consent

Written informed consent was obtained from all subjects for the publication of this report.

Competing interests

The authors declare that they have no competing interests.

Authors' contributions

BLT conducted genotyping and wrote the paper; BLT and HC performed statistical analysis; LL, SL and MCV designed research; PC was responsible for the medical follow-up; BLT and MCV have primary responsibility for final content. All authors read and approved the final manuscript.

Acknowledgements

We would like to thank Ann-Marie Paradis, Élisabeth Thifault, Véronique Garneau, Frédéric Guénard, Karelle Dugas-Bourdage, Catherine Ouellette, and Annie Bouchard-Mercier who contributed to the success of this study. We also thank Catherine Raymond for contributing to the laboratory work. IR and PC are recipients of a scholarship from the Fonds de recherche du Québec – Santé (FRQS). MCV is Tier 1 Canada Research Chair in Genomics Applied to Nutrition and Health. This work was supported by a grant from Canadian Institutes of Health Research (CIHR) – (MOP-110975).

Received: 16 September 2014 Accepted: 5 February 2015
Published online: 21 February 2015

References

1. World Health Organization. Global Status Report on Noncommunicable Diseases. Geneva: WHO Library Cataloguing-in-Publication Data; 2011.
2. Cullen P. Evidence that triglycerides are an independent coronary heart disease risk factor. Am J Cardiol. 2000;86:943–9.
3. Wang C, Harris WS, Chung M, Lichtenstein AH, Balk EM, Kupelnick B, et al. Differences in metabolic and transcriptomic profiles between responders and non-responders to an n-3 polyunsaturated fatty acids (PUFAs) supplementation. Genes Nutr. 2013;8:411–23.
4. Hui DY. Phospholipase A2(2) enzymes in metabolic and cardiovascular diseases. Curr Opin Lipidol. 2012;23:235–40.
5. Pratiko D. Prostanoid and isoprostane pathways in atherogenesis. Atherosclerosis. 2008;201:8–16.
6. Deigner HP. Hermetter A. Oxidized phospholipids: emerging lipid mediators in pathophysiology. Curr Opin Lipidol. 2008;19:289–94.
7. Das UN. Can endogenous lipid molecules serve as predictors and prognostic markers of coronary heart disease? Lipids Health Dis. 2008;7:19.
8. Shimizu T. Lipid mediators in health and disease: enzymes and receptors as therapeutic targets for the regulation of immunity and inflammation. Annu Rev Pharmacol Toxicol. 2009;49:123–50.
9. Cederas A, Jenkins CM, Mancuso DJ, Gross RW. Calcium-independent phospholipases in the heart: mediators of cellular signaling, bioenergetics, and ischemia-induced electrophysiologic dysfunction. J Cardiovasc Pharmacol. 2009;53:277–89.
10. Dennis EA, Gao J, Hsu YH, Magiotti V, Kokotos G. Phospholipase A2 enzymes: physical structure, biological function, disease implication, chemical inhibition, and therapeutic intervention. Chem Rev. 2011;111:1630–85.
11. Kugiyama K, Ota Y, Takaoze K, Motyama Y, Kawanoto H, Miyao Y, et al. Circulating levels of secretory type II phospholipase A2 predict coronary events in patients with coronary artery disease. Circulation. 1999;100:280–4.
12. Mallat Z, Steg PG, Benessiano J, Tanguy ML, Fox KA, Collet JP, et al. Circulating secretory phospholipase A2 activity predicts recurrent events in patients with severe acute coronary syndromes. J Am Coll Cardiol. 2005;46:1249–57.
13. Hartzala J, Li D, Conti DV, Wikman S, Patel E, Tang WH, et al. Genetic contribution of the leukotriene pathway to coronary artery disease. Hum Genet. 2011;129:17–27.
14. Callaway CW, Chumlea WC, Bouchard C, Himes JH, Lohman TG, Martin AD, et al. Standardization of Anthropometric Measurements : The Airile (VA) Consensus Conference. Champaign, IR, USA: Human Kinetics Publishers; 1988. p. 39–80.
15. McLarnara JR, Schaefer EJ. Automated enzymatic standardized lipid analyses for plasma and lipoprotein fractions, Clin Chim Acta. 1987;166:1–8.
16. Albers JJ, Wamick GR, Wiebe D, King P, Steiner P, Smith L, et al. Multi-laboratory comparison of three heparin-Mn2+ precipitation procedures for estimating cholesterol in high-density lipoprotein. Clin Chem. 1999;45:280–4.
17. Fiedwald WT, Levy RI, Fredrickson DS. Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without the use of the preparative ultracentrifuge. Clin Chem. 1972;18:499–502.
18. Lauro BC. Quantitative estimation of proteins by electrophoresis in agarose gel containing antibodies. Anal Biochem. 1966;15:45–52.
19. Pirro M, Bergeron J, Dagenais GR, Bernard PM, Cantin B, Despres JP, et al. Age and duration of follow-up as modulators of the risk for ischemic heart disease associated with high plasma C-reactive protein levels in men. Arch Intern Med. 2001;161:2474–80.
31. Shaikh NA, Downar E. Time course of changes in porcine myocardial phospholipid levels during ischemia. A reassessment of the lysophosphatidyl hypothesis. Circ Res. 1981;49:316–25.

32. Kroeger E, Verneau R, Carmichael PH, Lindsay J, Julien P, Dewailly E, et al. Omega-3 fatty acids and risk of dementia: the Canadian study of health and aging. Am J Clin Nutr. 2009;90:184–92.

33. Livak KJ. Allelic discrimination using fluorescent probes and the S'-nuclease assay. Genet Anal. 1999;14:13–9.

34. Miller M, Stone NL, Ballantyne C, Bittner V, Criqui MH, Ginsberg HN, et al. Association between polymorphisms in the fatty acid desaturase gene cluster and the plasma tracyglycerol response to an n-3 PUFA supplementation. Nutrients. 2012;4:1026–41.

35. Cormier H, Rudkowska I, Paradis AM, Thibault E, Gagneau V, Lemieux S, et al. Association between polymorphisms in the fatty acid desaturase gene cluster and plasma triacylglycerols in northern Chinese Han population. Atherosclerosis. 2008;196:81–85.

36. Sertic J, Skoric B, Lovric J, Bozina T, Reiner Z. Does Lp-PLA2 determination help predict atherosclerosis and cardiocerebrovascular disease? Acta Med Croatica. 2010;64:237–45.

37. Vittos O, Toana B, Vittos A, Moldoveanu E. Lipoprotein-associated phospholipase A2 (Lp-PLA2): a review of its role and significance as a cardiovascular biomarker. Biomarkers. 2011;17:289–302.

38. Tischfeld JA, Xia YR, Shih DM, Klisak I, Chen J, Engle SJ, et al. Low-molecular-weight, calcium-dependent phospholipase A2 genes are linked and map to homologous chromosome regions in mouse and human. Genomics. 1996;32:328–33.

39. Sato H, Kato R, Isogai Y, Saka G, Ohtsuki M, Taketomi Y, et al. Analyses of PLA2G7 gene polymorphisms with ischemic stroke in northern Chinese Han population. Neurosci Lett. 2006;392:246–50.

40. Tischfeld JA, Xia YR, Shih DM, Klisak I, Chen J, Engle SJ, et al. Low-molecular-weight, calcium-dependent phospholipase A2 genes are linked and map to homologous chromosome regions in mouse and human. Genomics. 1996;32:328–33.

41. Shaikh NA, Downar E. Time course of changes in porcine myocardial phospholipid levels during ischemia. A reassessment of the lysophosphatidyl hypothesis. Circ Res. 1981;49:316–25.

42. Kroeger E, Verneau R, Carmichael PH, Lindsay J, Julien P, Dewailly E, et al. Omega-3 fatty acids and risk of dementia: the Canadian study of health and aging. Am J Clin Nutr. 2009;90:184–92.

43. Livak KJ. Allelic discrimination using fluorescent probes and the S'-nuclease assay. Genet Anal. 1999;14:13–9.

44. Miller M, Stone NL, Ballantyne C, Bittner V, Criqui MH, Ginsberg HN, et al. Association between polymorphisms in the fatty acid desaturase gene cluster and the plasma triacylglycerol response to an n-3 PUFA supplementation. Nutrients. 2012;4:1026–41.